Patents by Inventor Christelle N. Soudy

Christelle N. Soudy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Thienopyrimidine inhibitors of atypical protein kinase C
    Patent number: 10954251
    Abstract: The present application provides a compound of formula (I) or a salt thereof, wherein R1, R2, R3, R4, R5, R6, A, G, M, Q and X are as defined herein. A compound of formula (I) and its salts have a PKC inhibitory activity, and may be used to treat proliferative disorders.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: March 23, 2021
    Assignee: Cancer Research Technology Limited
    Inventors: Bruce D. Dorsey, Keith S. Learn, Emma L. Morris, Gregory R. Ott, Jonathan R. A. Roffey, Christelle N. Soudy, Jason C. Wagner
  • Azaquinazoline inhibitors of atypical protein kinase C
    Patent number: 10414763
    Abstract: The present application provides a compound of formula (I) and/or a salt thereof, wherein R1, G, and X are as defined herein. A compound of formula (I) and/or its salts have aPKC inhibitory activity, and may be used to treat proliferative disorders. Compositions comprising a compound of Formula (I) and/or a salt thereof are also provided.
    Type: Grant
    Filed: March 25, 2015
    Date of Patent: September 17, 2019
    Assignee: Cancer Research Technology Limited
    Inventors: Bruce D. Dorsey, Benjamin J. Dugan, Katherine M. Fowler, Robert L. Hudkins, Eugen F. Mesaros, Nathaniel J T Monck, Emma L. Morris, Ikeoluwa Olowoye, Gregory R. Ott, Gregoire A. Pave, Jonathan R. A. Roffey, Christelle N. Soudy, Craig A. Zificsak, Allison L. Zulli
  • THIENOPYRIMIDINE INHIBITORS OF ATYPICAL PROTEIN KINASE C
    Publication number: 20190106433
    Abstract: The present application provides a compound of formula (I) or a salt thereof, wherein R1, R2, R3, R4, R5, R6, A, G, M, Q and X are as defined herein. A compound of formula (I) and its salts have a PKC inhibitory activity, and may be used to treat proliferative disorders.
    Type: Application
    Filed: December 6, 2018
    Publication date: April 11, 2019
    Inventors: Bruce D. DORSEY, Keith S. LEARN, Emma L. MORRIS, Gregory R. OTT, Jonathan R.A. ROFFEY, Christelle N. SOUDY, Jason C. WAGNER
  • Thienopyrimidine inhibitors of atypical protein kinase C
    Patent number: 10183950
    Abstract: The present application provides a compound of formula (I) or a salt thereof, wherein R1, R2, R3, R4, R5, R6, A, G, M, Q and X are as defined herein. A compound of formula (I) and its salts have aPKC inhibitory activity, and may be used to treat proliferative disorders.
    Type: Grant
    Filed: January 26, 2017
    Date of Patent: January 22, 2019
    Assignee: Cancer Research Technology Limited
    Inventors: Bruce D. Dorsey, Keith S. Learn, Emma L. Morris, Gregory R. Ott, Jonathan R. A. Roffey, Christelle N. Soudy, Jason C. Wagner
  • Azaquinazoline inhibitors of Atypical protein Kinase C
    Patent number: 9914730
    Abstract: The present application provides azaquinazoline compounds as defined herein. This application further describes compositions comprising the same. These azaquinazoline compounds and their salts have atypical protein kinase C (“aPKC”) inhibitory activity, and may be used to treat proliferative disorders.
    Type: Grant
    Filed: September 27, 2013
    Date of Patent: March 13, 2018
    Assignee: Cancer Research Technology Limited
    Inventors: Henry J. Breslin, Bruce D. Dorsey, Benjamin J Dugan, Katherine M. Fowler, Robert L Hudkins, Eugen F. Mesaros, Nathaniel J. T. Monck, Emma L. Morris, Ikeoluwa Olowoye, Gregory R. Ott, Gregoire A. Pave, Jonathan R. Roffey, Christelle N. Soudy, Ming Tao, Craig A. Zificsak, Allison L. Zulli
  • Azaquinazoline inhibitors of atypical protein kinase C
    Patent number: 9896446
    Abstract: The present application provides a compound of formula (I) or a salt thereof, wherein R7, R8, R9, G, and X are as defined herein. This application further describes compositions comprising the same. Compounds of formula (I) and their salts have aPKC inhibitory activity, and may be used to treat proliferative diseases.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: February 20, 2018
    Assignee: CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Henry J. Breslin, Bruce D. Dorsey, Benjamin J. Dugan, Robert L. Hudkins, Eugen F. Mesaros, Gregory R. Ott, Craig A. Zificsak, Allison L. Zulli, Ming Tao, Katherine M. Fowler, Emma L. Morris, Gregoire A. Pave, Jonathan R. A. Roffey, Nathaniel J. T. Monck, Christelle N. Soudy, Ikeoluwa Olowoye
  • THIENOPYRIMIDINE INHIBITORS OF ATYPICAL PROTEIN KINASE C
    Publication number: 20170158706
    Abstract: The present application provides a compound of formula (I) or a salt thereof, wherein R1, R2, R3, R4, R5, R6, A, G, M, Q and X are as defined herein. A compound of formula (I) and its salts have aPKC inhibitory activity, and may be used to treat proliferative disorders.
    Type: Application
    Filed: January 26, 2017
    Publication date: June 8, 2017
    Applicant: Cancer Research Technology Limited
    Inventors: Bruce D. Dorsey, Keith S. Learn, Emma L. Morris, Gregory R. Ott, Jonathan R.A. Roffey, Christelle N. Soudy, Jason C. Wagner
  • Thienopyrimidine inhibitors of atypical protein kinase C
    Patent number: 9604994
    Abstract: The present application provides a compound of formula (I) or a salt thereof, wherein R1, R2, R3, R4, R5, R6, A, G, M, Q and X are as defined herein. A compound of formula (I) and its salts have aPKC inhibitory activity, and may be used to treat proliferative disorders.
    Type: Grant
    Filed: May 22, 2014
    Date of Patent: March 28, 2017
    Assignee: Cancer Research Technology Limited
    Inventors: Bruce D Dorsey, Keith S. Learn, Emma L. Morris, Gregory R Ott, Jonathan R. A. Roffey, Christelle N. Soudy, Jason C. Wagner
  • Azaquinazoline Inhibitors of Atypical Protein Kinase C
    Publication number: 20160102094
    Abstract: The present application provides a compound of formula (1) or a salt thereof, wherein R7, R8, R9, G, and X are as defined herein. This application further describes compositions comprising the same. Compounds of formula (I) and their salts have aPKC inhibitory activity, and may be used to treat proliferative diseases.
    Type: Application
    Filed: December 18, 2015
    Publication date: April 14, 2016
    Applicants: IGNYTA, INC., Cancer Research Technology Limited
    Inventors: Henry J. Breslin, Bruce D. Dorsey, Benjamin J. Dugan, Robert L. Hudkins, Eugen F. Mesaros, Gregory R. Ott, Craig A. Zificsak, Allison L. Zulli, Ming Tao, Katherine M. Fowler, Emma L. Morris, Gregoire A. Pave, Jonathan R.A. Roffey, Nathaneil J.T. Monck, Christelle N. Soudy, Ikeoluwa Olowoye
  • Azaquinazoline Inhibitors Of Atypical Protein Kinase C
    Publication number: 20150274720
    Abstract: The present application provides a compound of formula (I) and/or a salt thereof, wherein R1, G, and X are as defined herein. A compound of formula (I) and/or its salts have aPKC inhibitory activity, and may be used to treat proliferative disorders. Compositions comprising a compound of Formula (I) and/or a salt thereof are also provided.
    Type: Application
    Filed: March 25, 2015
    Publication date: October 1, 2015
    Inventors: Bruce D. Dorsey, Benjamin J. Dugan, Katherine M. Fowler, Robert L. Hudkins, Eugen F. Mesaros, Nathaniel JT Monck, Emma L. Morris, Ikeoluwa Olowoye, Gregory R. Ott, Gregoire A. Pave, Jonathan R.A. Roffey, Christelle N. Soudy, Craig A. Zificsak, Allison L. Zulli
  • Thienopyrimidine Inhibitors of Atypical Protein Kinase C
    Publication number: 20140323435
    Abstract: The present application provides a compound of formula (I) or a salt thereof, wherein R1, R2, R3, R4, R5, R6, A, G, M, Q and X are as defined herein. A compound of formula (I) and its salts have aPKC inhibitory activity, and may be used to treat proliferative disorders.
    Type: Application
    Filed: May 22, 2014
    Publication date: October 30, 2014
    Applicants: Cancer Research Technology Limited, Cephalon, Inc.
    Inventors: Bruce D. Dorsey, Keith S. Learn, Emma L. Morris, Gregory R. Ott, Jonathan R.A. Roffey, Christelle N. Soudy, Jason C. Wagner
  • Azaquinazoline Inhibitors of Atypical Protein Kinase C
    Publication number: 20140113882
    Abstract: The present application provides a compound of formula (I) or a salt thereof, wherein R7, R8, R9, G, and X are as defined herein. This application further describes compositions comprising the same. Compounds of formula (I) and their salts have aPKC inhibitory activity, and may be used to treat proliferative disorders.
    Type: Application
    Filed: September 27, 2013
    Publication date: April 24, 2014
    Applicants: Cancer Research Technology Limited, Cephalon, Inc.
    Inventors: Henry J. Breslin, Bruce D. Dorsey, Benjamin J. Dugan, Katherine M. Fowler, Robert L. Hudkins, Eugen F. Mesaros, Nathaniel J.T. Monck, Emma L. Morris, Ikeoluwa Olowoye, Gregory R. Ott, Gregoire A. Pave, Jonathan R. Roffey, Christelle N. Soudy, Ming Tao, Craig A. Zificsak, Allison L. Zulli